

1222-2022  
800  
ANNI



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA

Corso di Dottorato di Ricerca in  
Medicina Specialistica Traslazionale "G.B. Morgagni"  
Coordinatore: Prof. Annalisa Angelini

## Convegno presentazione III anno (ciclo XXXIV)

Monteortone di Abano Terme (PD)  
Venerdì 10 Settembre 2021

Casa Religiosa di Ospitalità "Terme San Marco"  
Via Santuario n.130  
350131 Monteortone di Abano Terme (PD)

## ***DOTTORATO DI RICERCA: VISIONE E CORAGGIO***

***Prof. Manuel G. Cosio***

*Docente Dottorato di Ricerca, Università di Padova  
Professore Emerito McGill University, Montreal - Canada*

***Dott. Davide Biondini***

*Ricercatore Università di Padova, Dottore di Ricerca*

# *Search and Research*

- **SEARCH:** *Find something by looking around carefully*

Middle English: from Old French **cerchier** (verb), from late Latin **circare** 'go round', from Latin **circus** 'circle'

- **RESEARCH:** *In late 16th century: the Latin inseparable reinforcing prefix **re-** meaning: **again, back, once more seek out, search closely**, was added to Old French **cerchier** 'to search' to become **recerche** defined in 1630 as:*


***“Diligent scientific inquiry and investigation directed to the discovery of some fact”***

# VISION

- The ability to think about or plan the future with imagination or wisdom.

***Believe in your vision  
and do everything you  
can to turn it into  
reality.***


# ON EXCELLENCE



Aristotle

- Excellence is never an accident.
- It is always the result of high intention, sincere effort, and intelligent execution;
- It represents the wise choice of many alternatives – choice, not chance, determines your destiny.

# ON CREATIVITY



**Albert Einstein**

***•It is the supreme art of the teacher to awaken joy in creative expression and knowledge.***

***•And creativity is contagious.  
Spread it around***

# ON DOING RESEARCH

- *Success of research depends upon many factors*
- *The pivotal and initiating factor is the scientific curiosity of the investigator*
- *The important thing is not to stop questioning. Curiosity has its own reason for existing.*
- *Curiosity compels the discover - or uncover – of new data and new concepts.*

# ON DOING RESEARCH

ask the right question  
**Ask the  
right  
question**

**1. Having read the historical background of the problem you then need to ask the right question.**

**2. Formulate an Hypothesis.**

**Methods**

**Interpretation**


**Be coragious: Question PARADIGMS!**

# *Courage*

- The ability to do something that frightens one.
- ***“Lead your own life and have the courage of your convictions”***
- *ORIGIN Middle English (denoting the heart, as the seat of feelings):  
from Old French **corage**, from Latin **cor** ‘heart’.*



# ON COURAGE



You will never do anything in this **World**  
without **Courage**.

It is the greatest **Quality** of the mind  
next to **Honor**.

~Aristotle

# VISION ...

- 1) Learn from anyone around you




# VISION ...

- 1) Learn from anyone around you
- 2) Try to learn as much as possible, then focus on something more specific

# VISION ...

- 1) Learn from anyone around you
- 2) Try to learn as much as possible, then focus on something more specific
- 3) Moving concept

Lead II



# VISION ...

- 1) Learn from anyone around you
- 2) Try to learn as much as possible, then focus on something more specific
- 3) Moving concept

# VISION ...

- 1) Learn from anyone around you
- 2) Try to learn as much as possible, then focus on something more specific
- 3) Moving concept
- 4) Planning

# ... AND COURAGE


**coràggio** (dal latino *coratĭcum* o anche *cor habeo*, aggettivo derivante dalla parola composta *cōr, cōrdis* 'cuore' e dal verbo *habere* 'avere': *avere cuore*)

1. Forza d'animo nel sopportare con serenità e rassegnazione dolori fisici o morali, nell'affrontare con decisione un pericolo, nel dire o fare cosa che importi rischio o sacrificio:


2. Sfacciataggine, impudenza: *ha avuto il c. di negare; dopo ciò che ha fatto, ha ancora il c. di dichiararsi nostro amico; ci vuol proprio un bel c.!*



2017




2020



# Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis

Davide Biondini<sup>1</sup>, Elisabetta Balestro<sup>1</sup>, Donato Lacedonia<sup>2</sup>, Stefania Cerri<sup>3</sup>, Rosanna Milaneschi<sup>4</sup>, Fabrizio Luppi<sup>3</sup>, Elisabetta Cocconcelli<sup>1</sup>, Erica Bazzan<sup>1</sup>, Enrico Clini<sup>5</sup>, Maria Pia Foschino Barbaro<sup>2</sup>, Dario Gregori<sup>1</sup>, Manuel G Cosio<sup>1,6</sup>, Marina Saetta<sup>1</sup> & Paolo Spagnolo<sup>1</sup>

SCIENTIFIC REPORTS | (2018) 8:5961 | DOI:10.1038/s41598-018-24303-4





# MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment

Davide Biondini, Elisabetta Balestro, Chiara Rigobello, Simonetta Baraldo, Donato Lacedonia, Elisabetta Cocconcelli, Erica Bazzan, Maria Pia Foschino Barbaro, Manuel G Cosio, Marina Saetta, Paolo Spagnolo

European Respiratory Journal 2019; 44: PA1352; DOI: 10.1183/13993003.congress-2019.PA1352

Article

Info & Metrics

## Abstract

**Background:** A common variant within MUC5B promoter (rs35705950) is the strongest risk factor for sporadic and familial IPF, as well as a predictor of outcome. However, there are no data on the impact of MUC5B rs35705950 genotype on disease behavior in IPF patients on antifibrotic treatment.

**Aim:** To determine in a phenotypically well characterized population of IPF patients treated with antifibrotics whether MUC5B genotype impacts on disease progression and survival.

**Methods:** 69 IPF patients on antifibrotic treatment were followed-up from 2012 until transplantation, death or end of follow-up (December 2018). Disease progression was defined based on mL/year forced vital capacity (FVC) loss. All patients were genotyped for MUC5B rs35705950 by PCR amplification and Sanger sequencing.

**Results:** Mean follow-up during treatment was 36 months. Out of 69 patients, 46 (66.7%) carried the mutant T allele (GT or TT) and 23 (33.3%) did not (GG). Over the study period, carriage of the MUC5B rs35705950 T allele was not associated with a faster decline in FVC. Conversely, at the end of the follow-up, transplant-free survival was longer in carriers of the GT/TT genotype compared to the GG genotype (HR 0.38, 95% CI 0.14-1.04, p=0.05).

**Conclusions:** In IPF patients on antifibrotic treatment, carriage of the MUC5B rs35705950 T allele predicts survival, but not the magnitude of functional decline over time. This data highlights the utility of MUC5B genetic data in clinical decision making.

Vol 54 Issue suppl 63 [Table of Contents](#)

[Table of Contents](#)

[Index by author](#)

Biondini et al. *Respir Res* (2021) 22:98

<https://doi.org/10.1186/s12931-021-01694-z>


Respiratory Research

RESEARCH

Open Access



## Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment

Davide Biondini<sup>1†</sup>, Elisabetta Cocconcelli<sup>1†</sup>, Nicol Bernardinello<sup>1</sup>, Giulia Lorenzoni<sup>4</sup>, Chiara Rigobello<sup>2</sup>, Sara Lococo<sup>1</sup>, Gioele Castelli<sup>1</sup>, Simonetta Baraldo<sup>1</sup>, Manuel G. Cosio<sup>1,3</sup>, Dario Gregori<sup>4</sup>, Marina Saetta<sup>1</sup>, Elisabetta Balestro<sup>1†</sup> and Paolo Spagnolo<sup>1††</sup> 

HERE ARE MY CORRECTIONS. I WANT TO SEE IT AGAIN BEFORE YOU SUBMIT IT.



MAKES CORRECTIONS

# THE ENDLESS CYCLE?



MAKES EDITS

HERE'S THE LATEST DRAFT.

